Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab-IRDye800 for HNSCC imaging during surgery
NCT02415881Phase 1Completed
- Sponsor
- Eben Rosenthal
- Start
- Aug 2016
- Primary completion
- Nov 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of panitumumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Eben Rosenthal. Primary endpoint: Safety profile of panitumumab-IRDye800 at 30 days. Started Aug 2016; status: completed.
02
Drugs
panitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02415881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02415881.